221 related articles for article (PubMed ID: 33747966)
1. Progression Patterns, Treatment, and Prognosis Beyond Resistance of Responders to Immunotherapy in Advanced Non-Small Cell Lung Cancer.
Xu Y; Li H; Fan Y
Front Oncol; 2021; 11():642883. PubMed ID: 33747966
[TBL] [Abstract][Full Text] [Related]
2. The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.
Ying X; You G; Shao R
Transl Cancer Res; 2024 May; 13(5):2408-2418. PubMed ID: 38881915
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors beyond first-line progression with prior immunotherapy in patients with advanced non-small cell lung cancer.
Xu M; Hao Y; Zeng X; Si J; Song Z
J Thorac Dis; 2023 Apr; 15(4):1648-1657. PubMed ID: 37197488
[TBL] [Abstract][Full Text] [Related]
4. Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer.
Yu X; Chu X; Wu Y; Zhou J; Zhao J; Zhou F; Han C; Su C
Cancer Drug Resist; 2021; 4(3):728-739. PubMed ID: 35582303
[No Abstract] [Full Text] [Related]
5. Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.
Wang Z; Wei L; Li J; Zhou H; Li S; Chen D; Yu Y; Zhao L; Zhu X; Song Y
Transl Lung Cancer Res; 2021 Dec; 10(12):4368-4379. PubMed ID: 35070747
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety analysis of immune checkpoint inhibitor rechallenge therapy in locally advanced and advanced non-small cell lung cancer: a retrospective study.
Yan X; Zhao L; Wu F; Shen B; Zhou G; Feng J; Yue C; Zhu J; Yu S
J Thorac Dis; 2024 Mar; 16(3):1787-1803. PubMed ID: 38617775
[TBL] [Abstract][Full Text] [Related]
7. Resistance to immune checkpoint inhibitors in advanced lung cancer: Clinical characteristics, potential prognostic factors and next strategy.
Zhou J; Lu X; Zhu H; Ding N; Zhang Y; Xu X; Gao L; Zhou J; Song Y; Hu J
Front Immunol; 2023; 14():1089026. PubMed ID: 36776868
[TBL] [Abstract][Full Text] [Related]
8. Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC.
Xuzhang W; Huang H; Yu Y; Shen L; Li Z; Lu S
Ther Adv Med Oncol; 2023; 15():17588359231156387. PubMed ID: 36895853
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study.
Tian T; Yu M; Yu Y; Wang K; Tian P; Luo Z; Ding Z; Wang Y; Gong Y; Zhu J; Zou B; Sio TT; Alves A; Liu Y; Huang M; Lu Y
Transl Lung Cancer Res; 2022 Jun; 11(6):1027-1037. PubMed ID: 35832458
[TBL] [Abstract][Full Text] [Related]
10. The role of surgery in the treatment of oligoprogression after systemic treatment for advanced non-small cell lung cancer.
Joosten PJM; de Langen AJ; van der Noort V; Monkhorst K; Klomp HM; Veenhof AAFA; Dickhoff C; Smit EF; Hartemink KJ
Lung Cancer; 2021 Nov; 161():141-151. PubMed ID: 34600405
[TBL] [Abstract][Full Text] [Related]
11. [Interest of focal radiotherapy in case of oligoprogression under immunotherapy in the treatment of metastatic non-small cell lung cancer].
Gagé A; Pereira B; Belliere A; Janicot H; Jeannin G; Bourrachot C; Durand M; Rolland-Debord C; Merle P
Bull Cancer; 2023 Dec; 110(12):1234-1243. PubMed ID: 38445648
[TBL] [Abstract][Full Text] [Related]
12. Local Therapy for Oligoprogressive Disease in Patients With Advanced Stage Non-small-cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutation.
Qiu B; Liang Y; Li Q; Liu G; Wang F; Chen Z; Liu M; Zhao M; Liu H
Clin Lung Cancer; 2017 Nov; 18(6):e369-e373. PubMed ID: 28465010
[TBL] [Abstract][Full Text] [Related]
13. Oligoprogression of Solid Tumors on Immune Checkpoint Inhibitors: The Impact of Local Ablative Radiation Therapy.
Sindhu KK; Nehlsen AD; Lehrer EJ; Rowley JP; Stock RG; Galsky MD; Buckstein M
Biomedicines; 2022 Oct; 10(10):. PubMed ID: 36289743
[TBL] [Abstract][Full Text] [Related]
14. Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.
Yang Y; Ai X; Xu H; Yang G; Yang L; Hao X; Yang K; Mi Y; Wang G; Zhang S; Lei S; Wang Y
Thorac Cancer; 2022 Dec; 13(23):3295-3303. PubMed ID: 36218023
[TBL] [Abstract][Full Text] [Related]
15. Local microwave ablation with continued EGFR tyrosine kinase inhibitor as a treatment strategy in advanced non-small cell lung cancers that developed extra-central nervous system oligoprogressive disease during EGFR tyrosine kinase inhibitor treatment: A pilot study.
Ni Y; Bi J; Ye X; Fan W; Yu G; Yang X; Huang G; Li W; Wang J; Han X; Ni X; Wei Z; Han M; Zheng A; Meng M; Xue G; Zhang L; Wan C
Medicine (Baltimore); 2016 Jun; 95(25):e3998. PubMed ID: 27336903
[TBL] [Abstract][Full Text] [Related]
16. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non-small cell lung cancer with sensitive EGFR mutations.
Zhang Y; Wang J; Yu Z; Ge H; Zhang LW; Feng LX
Clin Transl Sci; 2021 May; 14(3):890-897. PubMed ID: 33382908
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression.
Friedes C; Yegya-Raman N; Zhang S; Iocolano M; Cohen RB; Aggarwal C; Thompson JC; Marmarelis ME; Levin WP; Cengel KA; Ciunci CA; Singh AP; D'Avella C; Davis CW; Langer CJ; Feigenberg SJ
Clin Lung Cancer; 2024 Jan; 25(1):50-60.e6. PubMed ID: 37813713
[TBL] [Abstract][Full Text] [Related]
19. [The efficacy and prognostic factors of immunotherapy in advanced non-small cell lung cancer patients with different driver gene mutations].
Ma SX; Ma N; Han J; He Z; Wang L; Wang Q
Zhonghua Yi Xue Za Zhi; 2022 Apr; 102(13):922-929. PubMed ID: 35385963
[No Abstract] [Full Text] [Related]
20. Real World Experience of Crizotinib in 104 Patients With ALK Rearrangement Non-small-cell Lung Cancer in a Single Chinese Cancer Center.
Liu C; Yu H; Long Q; Chen H; Li Y; Zhao W; Zhao K; Zhu Z; Sun S; Fan M; Chang J; Wang J
Front Oncol; 2019; 9():1116. PubMed ID: 31696059
[No Abstract] [Full Text] [Related]
[Next] [New Search]
